Cognition Therapeutics (CGTX) Research & Development (2020 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Research & Development of $6.1 million for Q1 2026, down 43.26% year-over-year from $10.8 million in Q1 2025, and down 83.44% quarter-over-quarter from $37.0 million in Q4 2025.
Cognition Therapeutics (CGTX) Research & Development (2020 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Research & Development for 7 consecutive years, with $6.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 43.26% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $58.3 million (up 13435.73% YoY), while the FY2025 annual figure was $37.2 million, up 18681.31% from the prior year.
- Research & Development slipped to $6.1 million in Q1 2026 per CGTX's latest filing, from $37.0 million in the prior quarter.
- Across five years, Research & Development topped out at $37.0 million in Q4 2025 and bottomed at -$33.3 million in Q4 2024.
- Historically, Research & Development has averaged $8.1 million across 5 years, with a median of $10.6 million in 2024.
- Annual changes were most pronounced in 2024 — Research & Development tumbled 387.28% — and 2025, when it soared 210.93%.
- Cognition Therapeutics' Research & Development stood at $8.3 million in 2022, then jumped by 40.3% to $11.6 million in 2023, then sank by 387.28% to -$33.3 million in 2024, then jumped by 210.93% to $37.0 million in 2025, then slumped by 83.44% to $6.1 million in 2026.
- Business Quant data shows CGTX's Research & Development at $6.1 million in Q1 2026, $37.0 million in Q4 2025, and $3.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | 5.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.10 Mn |
| Mar 31, 2026 | 6.12 Mn |
| Dec 31, 2025 | 36.97 Mn |
| Sep 30, 2025 | 3.77 Mn |
| Jun 30, 2025 | 11.48 Mn |
| Mar 31, 2025 | 10.79 Mn |
| Dec 31, 2024 | -33.32 Mn |
| Sep 30, 2024 | 11.39 Mn |
| Jun 30, 2024 | 11.58 Mn |
| Mar 31, 2024 | 10.55 Mn |
| Dec 31, 2023 | 11.60 Mn |
| Sep 30, 2023 | 11.67 Mn |
| Jun 30, 2023 | 8.50 Mn |
| Mar 31, 2023 | 5.43 Mn |
| Sep 30, 2022 | 8.27 Mn |
| Mar 31, 2022 | 6.52 Mn |
| Sep 30, 2021 | 3.68 Mn |
| Sep 30, 2020 | 3.40 Mn |